The global leader's innovative regenerative medical technology and devices vastly improve patient outcomes and reduce overall medical costs. SINGAPORE, Nov. 8, 2022 /PRNewswire/ Osteopore International (ASX:OSX) ("Osteopore", "OSX" or the "Company"), a Singapore- and Australia-based med-tech company focusing on facilitating natural tissue regeneration, is primed for the global limelight after quietly developing and commercialising its novel 3D-printed bioresorbable scaffold implants that have the potential to revolutionise the way surgeons help patients to naturally regrow bones and other tissues. Left to Right: Mark Leong, Executive Chairman of Osteopore, Goh Khoon Seng, CEO of Osteopore and Lim Jing, COO & CTO of Osteopore Osteopore leverages technology that has been researched and developed in Singapore and its patent-protected 3D-printed scaffold implants use a bioresorbable material to mimic the complex and inter-connected microstructure of b